It has been suggested that the retinal degeneration measured as GCIP or pRNFL could serve as an estimate of the global brain atrophy seen in MS, and that OCT is a useful tool for clinical monitoring and as outcome in investigative trials (8, 12, 39, 40). Here, CCNDBP1 is linked to myeloid sarcoma.